drugset / Trial / NCT04524390

Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai

NCT04524390

Phase 2 Completed 75 enrolled Mirum Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A study to evaluate the efficacy and safety of maralixibat in infants with Biliary Atresia (BA) after Hepatoportoenterostomy (HPE, also known as the Kasai procedure).

Timeline

Start
2021-07-08
Primary completion
2023-11-07
Completion
2024-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Maralixibat Small molecule

Indications